ArticleDiscover oncology2026
Establishment and validation of a prognostic model for oral squamous cell carcinoma based on ribosomal and apoptosis-related gene expression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) is a major cause of cancer-related mortality worldwide. This study aimed to identify differentially expressed ribosomal and apoptosis-related genes (RARGs) in OSCC and develop a gene-based prognostic model to improve patient stratification and outcome predictions.
methodsGene expression profiles were analyzed from The Cancer Genome Atlas (TCGA) OSCC cohort (328 OSCC samples and 32 control samples) and Gene Expression Omnibus datasets (GEO, GSE2355827: 27 OSCC samples and 5 control samples, and GSE25099: 57 OSCC samples and 22 control samples). A total of 849 RARGs were obtained from GeneCards and PubMed databases. Overlaps between differentially expressed genes (DEGs) and RARGs were identified and prognostic genes were selected using Cox regression analysis. These data were used to construct a risk model. The prognostic performance was validated using time-dependent receiver operating characteristic curves and Kaplan–Meier survival analysis. Key gene expression was validated by qRT-PCR.
resultsWe identified 3,513 DEGs in the TCGA-OSCC dataset, including 1,721 upregulated and 1,792 downregulated genes. Thirty-two ribosomal and apoptosis-related DEGs were identified. Survival analysis demonstrated significant differences in overall survival rates between the high- and low-risk groups. Six genes (SLC25A4, PLAU, IGF2BP2, CDKN2A, CCL26, and ALB) were incorporated into the final model, which achieved ROC-AUC scores above 0.6 for 1-, 2-, and 3-year survival predictions. qRT-PCR was performed to validate the expression patterns of Six genes.
conclusionThis study revealed the potential mechanism link between abnormal ribosome production and unbalanced apoptosis in OSCC. Based on this assumption, a prognostic model for RARGs expression characteristics was constructed. This model integrates the intrinsic molecular characteristics of tumors with systemic factors such as host nutrition and inflammation, enhances biological interpretation, and provides new ideas for patient individualized prognosis assessment and treatment decisions. Its stability and clinical practicality need to be further verified in a larger, multi-center population in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.